Recent studies have shown that MRI demonstrates promising results for evaluating the
chemotherapy efficacy in bone sarcomas. This article reviews current methods for evaluating …

Osteosarcoma (OS) is the most prevalent malignant bone tumor in adolescents and young
adults. OS cells grow in a permissive local microenvironment which modulates their …

Accumulating evidence has demonstrated that F‐box protein 22 (FBXO22) participates in
tumour development and progression in various types of human malignancies. However, the …

There has been no significant efficacy in treating osteosarcoma (OS) metastasis after nearly
four decades of trials. This motivates us to elucidate OS therapies using their four …

Purpose Anlotinib, a tyrosine kinase inhibitor (TKI) has been in clinical application to inhibit
malignant cell growth and lung metastasis in osteosarcoma (OS). However, a variety of drug …

Osteosarcoma is an aggressive bone malignancy with a high propensity for drug resistance
and metastasis, leading to poor clinical outcomes. This study investigates the role of core 1 …

Prostate cancer (PCa) with a high incidence worldwide is a serious threat to men's health.
Despite the continuous development of treatment strategies for PCa in recent years, the long …

Uncontrolled activation of c-Kit is closely related to the pathogenesis and progression of
leukemia, gastrointestinal cancer, and other malignant diseases. Although there are several …

Osteosarcoma is a common primary malignant bone tumor in adolescents. Wnt/β-catenin
has been proved to play a pro-oncogenic role and was overactivated in osteosarcoma …

Background Osteosarcoma, a tumor that originates from bone cells, has a poor prognosis
and a high degree of malignancy. Anlotinib, a small-molecule multi-target tyrosine kinase …